Cagrilintide
Long-acting amylin analogue researched in combination with GLP-1 agonists
Half-life
~7 days
Typical Dose
0.3-2.4mg weekly
Format
Injectable
Purity
≥98%
Overview
Cagrilintide is a long-acting amylin analogue. When combined with Semaglutide (CagriSema), it produces enhanced weight reduction effects beyond Semaglutide alone.
Mechanism
Amylin receptor agonist that complements GLP-1 mechanisms. Amylin slows gastric emptying and increases satiety through different pathways than GLP-1.
Researched benefits
- Synergistic with GLP-1 agonists
- Reduced food cravings
- Improved satiety
- Once-weekly dosing
Frequently asked
What is cagrilintide?
Cagrilintide is a long-acting amylin analog designed for once-weekly subcutaneous dosing. Amylin is co-secreted with insulin from pancreatic beta cells and acts on the area postrema to slow gastric emptying and promote satiety. Cagrilintide is studied both as monotherapy and paired with semaglutide.
How does cagrilintide differ from semaglutide?
They hit different receptors. Semaglutide is a GLP-1 receptor agonist; cagrilintide targets amylin and calcitonin receptors. Because the pathways are separate, the two are studied in combination on the hypothesis that effects add rather than overlap.
What is CagriSema?
CagriSema is the fixed-dose combination of cagrilintide and semaglutide, both at 2.4 mg weekly, evaluated in the REDEFINE and REIMAGINE Phase 3 programs. It is the most advanced amylin plus GLP-1 pairing in clinical development.
How is cagrilintide dosed in trials?
Trial protocols use once-weekly subcutaneous injection with stepwise escalation over several weeks to limit gastrointestinal side effects. Escalation schedules mirror the approach used for GLP-1 agonists.
Ready to start your research
Get Cagrilintide from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy Cagrilintide now